Turcot syndrome: all 60 studies

Page 1 of 1. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.

• Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI TumorsRecruitingNCT07829081
• A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT07807800Phase 1/2
• ABCSG R07 Rectal Cancer RegistryRecruitingNCT07780305
• MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastrointestinal CancersNot yet recruitingNCT07625735
• Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease DetectionRecruitingNCT07450612
• Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2
• Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyNot yet recruitingNCT07385846Phase 1
• Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial CancerNot yet recruitingNCT07369986Phase 2
• Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch SyndromeNot yet recruitingNCT07360834Not applicable
• Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNot yet recruitingNCT07266025Phase 2
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsRecruitingNCT07262619Phase 1/2
• Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07259473Phase 2
• A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsRecruitingNCT07213609Phase 1/2
• Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerRecruitingNCT06903858Phase 2
• Lynch Syndrome X-Talk of Enteral Mucosa With Immune SystemRecruitingNCT06708429
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 2
• PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial CancerRecruitingNCT06549855Not applicable
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 1
• SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)RecruitingNCT06278857Phase 2
• Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal CancerNot yet recruitingNCT05913570Phase 2
• Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05729646Phase 2
• Prostate Cancer Genetic Risk Evaluation and Screening StudyRecruitingNCT05129605
• Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal CancerRecruitingNCT04636008Phase 1/2
• Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerRecruitingNCT03926338Phase 2
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
• Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT01793168
• Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
• SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03894618Phase 1Results posted
• Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004TerminatedNCT03050814Phase 2Results posted
• Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersTerminatedNCT02992964Phase 1/2Results posted
• Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT07838246
• Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)Active, not recruitingNCT07461246
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsActive, not recruitingNCT06710847Phase 1/2
• Neoadjuvant Immunotherapy for T4 dMMR Colon CancerActive, not recruitingNCT06215677Phase 2
• Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 1
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
• Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.Active, not recruitingNCT05838768Phase 1
• Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerActive, not recruitingNCT05426005Phase 1/2
• Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT05371197Phase 2
• Frequency of Endometrial Cancer Precursors Associated with Lynch SyndromeCompletedNCT05257057
• T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/2
• Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for OxaliplatinActive, not recruitingNCT05118724Phase 2
• A Beta-only IL-2 ImmunoTherapY StudyActive, not recruitingNCT05086692Phase 1/2
• Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 1
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and SurvivalCompletedNCT04482608
• A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationActive, not recruitingNCT04104893Phase 2
• Anti-PD-1 +/- RT for MSI-H Solid TumorsWithdrawnNCT04001101Phase 2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 2
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• Avelumab for MSI-H or POLE Mutated Metastatic Colorectal CancerStatus unknownNCT03150706Phase 2
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 1
• Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingNCT02983578Phase 2
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1

← Turcot syndrome overview